CapEx at other companies
Other financials
Where this comes from
Reported directly by Taysha Gene Therapies, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The official record: Taysha Gene Therapies, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Taysha Gene Therapies, Inc.'s capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Taysha Gene Therapies, Inc.'s capex?
- Taysha Gene Therapies, Inc. (TSHA) reported capex of $24K in Q1 2026.
- How has Taysha Gene Therapies, Inc.'s capex changed year-over-year?
- Taysha Gene Therapies, Inc.'s capex decreased by 93.7% year-over-year, from $378K to $24K.
- What is the long-term trend for Taysha Gene Therapies, Inc.'s capex?
- Over 3 years (2021 to 2025), Taysha Gene Therapies, Inc.'s capex has grown at a -63.6% compound annual growth rate (CAGR), from $15.3M to $738K.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.